¼¼°èÀÇ ÆÄºê¸®º´ ½ÃÀå º¸°í¼­(2025³â)
Fabry Disease Global Market Report 2025
»óǰÄÚµå : 1760532
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,217,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 8,987,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,756,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ÆÄºê¸®º´ ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³â µ¿¾È °­·ÂÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2029³â±îÁö 8.0%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)·Î 31¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾È ¼ºÀåÀÇ ¿øµ¿·ÂÀº ½Å»ý¾Æ ¼±º°°Ë»ç ÇÁ·Î±×·¥ È®´ë, Èñ±ÍÁúȯ Ä¡·á¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ Áö¿ø, º¸´Ù ±¤¹üÀ§ÇÑ ÀÇ·á Á¢±Ù¼º, ¿ø°ÝÀÇ·á ¹× ¿ø°ÝÁø·áÀÇ ºÎ»ó, ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ±âÀÎÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÀÌ ±â°£ÀÇ ÁÖ¿ä µ¿ÇâÀ¸·Î´Â È¿¼Ò ´ëü ¿ä¹ýÀÇ Ã¤ÅÃ, À¯ÀüÀÚ °Ë»çÀÇ ¹ßÀü, Á¶±â ¹ß°ßÀ» À§ÇÑ AI¿Í µðÁöÅÐ µµ±¸ÀÇ ÅëÇÕ, AI¸¦ Ȱ¿ëÇÑ Áø´Ü ¾Ë°í¸®Áò, À¯ÀüÀÚ Ä¡·áÀÇ ¹ßÀü µîÀ» ²ÅÀ» ¼ö ÀÖ½À´Ï´Ù.

°³ÀθÂÃãÀÇ·áÀÇ Á߿伺ÀÌ ºÎ°¢µÇ¸é¼­ ÇâÈÄ ÆÐºê¸®º´ ½ÃÀåÀÇ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. ¸ÂÃãÇü ÀÇ·á´Â °³ÀÎÀÇ À¯ÀüÀû üÁú, ȯ°æ, ¶óÀÌÇÁ½ºÅ¸ÀÏ¿¡ µû¶ó Ä¡·á¸¦ Á¶Á¤ÇÏ¿© Ä¡·á °á°ú¸¦ Çâ»ó½Ãŵ´Ï´Ù. ÀÌ Á¢±Ù¹ýÀº ƯÁ¤ ȯÀÚÀÇ Çʿ信 µû¶ó Ä¡·á¸¦ ¸ÂÃãÈ­ÇÏ¿© Ä¡·á È¿°ú¸¦ ³ôÀÌ°í ºÎÀÛ¿ëÀ» ÁÙÀÓÀ¸·Î½á Ä¡·á È¿°ú¸¦ ³ôÀÔ´Ï´Ù. ¸ÂÃãÀÇ·á´Â ȯÀÚº° À¯ÀüÀÚ º¯ÀÌ ¹× Áúº´ ÁßÁõµµ¸¦ °í·ÁÇÑ Ä¡·á °èȹÀ» °³¹ßÇÒ ¼ö ÀÖ¾î Ä¡·á °á°ú¸¦ °³¼±ÇÏ°í ºÎÀÛ¿ëÀ» °¨¼Ò½Ãų ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 2¿ù ¹Ì±¹ ºñ¿µ¸®´ÜüÀÎ °³ÀθÂÃãÀǷῬÇÕ(Personalized Medicine Coalition)Àº FDA°¡ 2023³â Èñ±ÍÁúȯ ȯÀÚ¸¦ À§ÇØ »õ·Î ½ÂÀÎÇÑ °³ÀθÂÃãÄ¡·áÁ¦´Â 16°ÇÀ¸·Î 2022³â 6°Çº¸´Ù Å©°Ô Áõ°¡Çß´Ù°í ÁöÀûÇß½À´Ï´Ù. ÀÌ¿¡ µû¶ó ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁø °ÍÀÌ ÆÄºê¸®º´ ½ÃÀå È®´ë¸¦ ÃËÁøÇÏ´Â Áß¿äÇÑ ¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù.

ÆÄºê¸®º´ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷µéÀº PEGÈ­ È¿¼Ò´ëü¿ä¹ý(ERT)°ú °°Àº Çõ½ÅÀûÀÎ Ä¡·á¹ý¿¡ ÁýÁßÇÏ¿© Ä¡·á °á°ú¸¦ °³¼±Çϰí, ȯÀÚÀÇ ¼øÀÀµµ¸¦ ³ôÀ̸ç, ±âÁ¸ ERT¿Í °ü·ÃµÈ ¸é¿ª°è ¹ÝÀÀÀ» ¿ÏÈ­Çϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. Æú¸®¿¡Æ¿·» ±Û¸®ÄÝ(PEG)À» ÷°¡ÇÏ¿© ¾ÈÁ¤¼ºÀ» Çâ»ó½ÃÄÑ Ã¼³» Åõ¿© ±â°£À» ¿¬ÀåÇÏ°í ¸é¿ª¹ÝÀÀÀ» ÃÖ¼ÒÈ­ÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 5¿ù Chiesi ±×·ì¿¡ ¼ÓÇÑ Chiesi Global Rare Diseases´Â ¹Ì±¹ ½ÄǰÀǾ౹(FDA)ÀÌ PRX-102(pegunigalsidase alfa)¸¦ ¼ºÀÎ ÆÄºê¸®º´ ȯÀÚÀÇ Ä¡·áÁ¦·Î ½ÂÀÎÇß´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. À̹ø ½ÂÀÎÀº 140¸í ÀÌ»óÀÇ È¯ÀÚ¸¦ ´ë»óÀ¸·Î ÇÑ Á¾ÇÕÀûÀÎ ÀÓ»ó ÇÁ·Î±×·¥°ú ÃÖ´ë 7.5³âÀÇ Àå±â ÃßÀû°üÂûÀ» ÅëÇØ º» Ä¡·áÁ¦°¡ ¿ì¼öÇÑ ¾ÈÀü¼º ÇÁ·ÎÆÄÀϰú ÇÔ²² ½ÅÀåÀÇ Gb3 Ä§Âø¹° °¨¼Ò ¹× ½ÅÀå ±â´É À¯Áö¿¡ È¿°úÀûÀÓÀ» ÀÔÁõÇÑ µ¥ µû¸¥ °ÍÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ª ÀüÀï°ú °ü¼¼, ±×¸®°í Äڷγª¿Í ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°¡¤±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷°ú Çõ½ÅÀû ±â¾÷

Á¦32Àå ¼¼°èÀÇ ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´

Á¦34Àå ÃÖ±ÙÀÇ ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀå ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Fabry disease is an uncommon genetic condition resulting from a shortage of the enzyme alpha-galactosidase A, which causes fat to accumulate in the cells and organs of the body. Treatment aims to alleviate symptoms, prevent further organ damage, and enhance the quality of life for those affected.

Fabry disease has several forms, including types 1, 2, and others. Type 1 Fabry disease, a rare genetic disorder that typically starts in childhood, is caused by a near-total absence of the alpha-galactosidase A enzyme, leading to the accumulation of fat in cells and organs. Treatment options include enzyme replacement therapy, oral medications, adjunct therapies, and additional methods. Diagnosis is achieved through various techniques, including blood tests, genetic testing, parenteral tests, and other diagnostic approaches. Distribution channels for treatment include hospital pharmacies, online pharmacies, and retail pharmacies, serving different end users such as hospitals, homecare providers, specialty clinics, and other healthcare facilities.

The fabry disease market research report is one of a series of new reports from The Business Research Company that provides fabry disease market statistics, including the fabry disease industry global market size, regional shares, competitors with the fabry disease market share, detailed fabry disease market segments, market trends, and opportunities, and any further data you may need to thrive in the fabry disease industry. This fabry disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The fabry disease market size has grown strongly in recent years. It will grow from $2.10 billion in 2024 to $2.28 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth observed in the historical period can be credited to factors such as heightened awareness and diagnosis of rare diseases, the development of specialized healthcare infrastructure, government incentives and orphan drug designations, increased funding for rare disease research, and the initial introduction of therapies.

The fabry disease market size is expected to see strong growth in the next few years. It will grow to $3.10 billion in 2029 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period is expected to be driven by the expansion of newborn screening programs, regulatory support for orphan and rare disease treatments, broader healthcare access, the rise of telemedicine and remote care, and a growing demand for personalized medicine. Key trends during this period include the adoption of enzyme replacement therapy, advancements in genetic testing, the integration of AI and digital tools for early detection, AI-powered diagnostic algorithms, and progress in gene therapy.

The increasing emphasis on personalized medicine is anticipated to drive the growth of the Fabry disease market in the future. Personalized medicine tailors treatments based on an individual's genetic makeup, environment, and lifestyle, which improves treatment outcomes. This approach enhances treatment effectiveness and reduces side effects by customizing therapies to meet specific patient needs. Personalized medicine enables the development of treatment plans that consider a patient's unique genetic mutation and disease severity, resulting in better outcomes and fewer adverse effects. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based non-profit, noted that the FDA approved 16 new personalized treatments for rare disease patients in 2023, a significant rise from six approvals in 2022. As a result, the growing emphasis on personalized medicine is a key factor driving the expansion of the Fabry disease market.

Major companies in the Fabry disease market are focusing on innovative therapies, such as PEGylated enzyme replacement therapy (ERT), to improve treatment outcomes, enhance patient adherence, and reduce immune system reactions linked to traditional ERT. PEGylated ERT is a modified version of standard ERT, where polyethylene glycol (PEG) is added to the enzyme to improve stability, extend its duration in the body, and minimize immune responses. For example, in May 2023, Chiesi Global Rare Diseases, part of the Chiesi Group, announced that the U.S. Food and Drug Administration (FDA) approved PRX-102 (pegunigalsidase alfa) for the treatment of adult Fabry disease patients. The approval was supported by a comprehensive clinical program involving over 140 patients and long-term follow-up of up to 7.5 years, demonstrating the therapy's effectiveness in reducing kidney Gb3 deposits and maintaining kidney function, with a favorable safety profile.

In June 2022, Kyorin, a Japan-based pharmaceutical company, acquired a license from CellGenTech to develop and commercialize a treatment for Fabry disease. With this acquisition, Kyorin intends to leverage CellGenTech's genetically modified human adipocytes (GMAC) technology to create a new treatment for Fabry disease. CellGenTech Inc. is a biotechnology company from Japan that specializes in ex vivo gene therapy solutions for rare diseases, including Fabry disease.

Major players in the fabry disease market are Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, JCR Pharmaceuticals Co. Ltd., Sumitomo Pharma Co. Ltd, Chiesi Farmaceutici S.p.A., Amicus Therapeutics Inc., Idorsia Pharmaceuticals Ltd, Sangamo Therapeutics Inc., uniQure N.V., Protalix BioTherapeutics Inc., Spur Therapeutics Inc., Exegenesis Bio Inc., ISU ABXIS Co. Ltd., Eleva GmbH, AceLink Therapeutics Inc., 4D Molecular Therapeutics Inc., iBio Inc., Freeline Therapeutics Holdings plc, Greenovation Biotech GmbH.

North America was the largest region in the fabry disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in fabry disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the fabry disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The fabry disease market consists of revenues earned by entities by providing services such as genetic counseling, patient support programs, clinical trials and research services, and disease monitoring and management services. The market value includes the value of related goods sold by the service provider or contained within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Fabry Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on fabry disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for fabry disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The fabry disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Fabry Disease Market Characteristics

3. Fabry Disease Market Trends And Strategies

4. Fabry Disease Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Fabry Disease Growth Analysis And Strategic Analysis Framework

6. Fabry Disease Market Segmentation

7. Fabry Disease Market Regional And Country Analysis

8. Asia-Pacific Fabry Disease Market

9. China Fabry Disease Market

10. India Fabry Disease Market

11. Japan Fabry Disease Market

12. Australia Fabry Disease Market

13. Indonesia Fabry Disease Market

14. South Korea Fabry Disease Market

15. Western Europe Fabry Disease Market

16. UK Fabry Disease Market

17. Germany Fabry Disease Market

18. France Fabry Disease Market

19. Italy Fabry Disease Market

20. Spain Fabry Disease Market

21. Eastern Europe Fabry Disease Market

22. Russia Fabry Disease Market

23. North America Fabry Disease Market

24. USA Fabry Disease Market

25. Canada Fabry Disease Market

26. South America Fabry Disease Market

27. Brazil Fabry Disease Market

28. Middle East Fabry Disease Market

29. Africa Fabry Disease Market

30. Fabry Disease Market Competitive Landscape And Company Profiles

31. Fabry Disease Market Other Major And Innovative Companies

32. Global Fabry Disease Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Fabry Disease Market

34. Recent Developments In The Fabry Disease Market

35. Fabry Disease Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â